240 related articles for article (PubMed ID: 20102997)
1. Care of the cancer survivor: metabolic syndrome after hormone-modifying therapy.
Redig AJ; Munshi HG
Am J Med; 2010 Jan; 123(1):87.e1-6. PubMed ID: 20102997
[TBL] [Abstract][Full Text] [Related]
2. Metabolic syndrome after hormone-modifying therapy: risks associated with antineoplastic therapy.
Redig AJ; Munshi HG
Oncology (Williston Park); 2010 Aug; 24(9):839-44. PubMed ID: 20923040
[TBL] [Abstract][Full Text] [Related]
3. Sex steroid induced apoptosis as a rational strategy to treat anti-hormone resistant breast and prostate cancer.
Jordan VC; Fan P; Abderrahman B; Maximov PY; Hawsawi YM; Bhattacharya P; Pokharel N
Discov Med; 2016 May; 21(117):411-27. PubMed ID: 27355337
[TBL] [Abstract][Full Text] [Related]
4. Metabolic changes in patients with prostate cancer during androgen deprivation therapy.
Mitsuzuka K; Arai Y
Int J Urol; 2018 Jan; 25(1):45-53. PubMed ID: 29052905
[TBL] [Abstract][Full Text] [Related]
5. Metabolic complications of androgen deprivation therapy for prostate cancer.
Saylor PJ; Smith MR
J Urol; 2009 May; 181(5):1998-2006; discussion 2007-8. PubMed ID: 19286225
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular risks of androgen deprivation therapy.
Ribeiro AF; Camara C; Segre CA; Srougi M; Serrano CV
Arq Bras Cardiol; 2010 Sep; 95(3):412-5. PubMed ID: 20944900
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
Shahani S; Braga-Basaria M; Basaria S
J Clin Endocrinol Metab; 2008 Jun; 93(6):2042-9. PubMed ID: 18349064
[TBL] [Abstract][Full Text] [Related]
8. Cancer treatment-induced bone loss in breast and prostate cancer.
Saad F; Adachi JD; Brown JP; Canning LA; Gelmon KA; Josse RG; Pritchard KI
J Clin Oncol; 2008 Nov; 26(33):5465-76. PubMed ID: 18955443
[TBL] [Abstract][Full Text] [Related]
9. [Castration of prostate cancer patients and cognition].
Portin R; Koskinen A; Helenius H; Nurmi M; Salminen E
Duodecim; 2005; 121(16):1784-5. PubMed ID: 16268226
[No Abstract] [Full Text] [Related]
10. Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study.
Ng HS; Koczwara B; Roder D; Vitry A
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):403-410. PubMed ID: 29720722
[TBL] [Abstract][Full Text] [Related]
11. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
[TBL] [Abstract][Full Text] [Related]
12. Incidence and management of gynecomastia in men treated for prostate cancer.
Dobs A; Darkes MJ
J Urol; 2005 Nov; 174(5):1737-42. PubMed ID: 16217274
[TBL] [Abstract][Full Text] [Related]
13. Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer.
Higano CS
Urol Oncol; 2020 Dec; 38(12):912-917. PubMed ID: 32900627
[TBL] [Abstract][Full Text] [Related]
14. Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer.
Abrahamsson PA; Anderson J; Boccon-Gibod L; Schulman C; Studer UE; Wirth M
Eur Urol; 2005 Dec; 48(6):900-5. PubMed ID: 16257109
[TBL] [Abstract][Full Text] [Related]
15. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
Scherr DS; Pitts WR
J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
[TBL] [Abstract][Full Text] [Related]
16. Complications of androgen-deprivation therapy in prostate cancer: the other side of the coin.
Hoffmann P; Schulman C
BJU Int; 2009 Apr; 103(8):1020-3. PubMed ID: 19348058
[No Abstract] [Full Text] [Related]
17. [Metabolic syndrome and insulin resistance in patients with prostate cancer treated with androgen deprivation hormone].
Terrier JE; Mottet N
Prog Urol; 2013 Feb; 23(2):88-95. PubMed ID: 23352300
[TBL] [Abstract][Full Text] [Related]
18. Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer.
Harrington JM; Schwenke DC; Epstein DR; Bailey DE
Oncol Nurs Forum; 2014 Jan; 41(1):21-9. PubMed ID: 24368236
[TBL] [Abstract][Full Text] [Related]
19. Complications of androgen-deprivation therapy for prostate cancer.
Holzbeierlein JM; Castle EP; Thrasher JB
Clin Prostate Cancer; 2003 Dec; 2(3):147-52. PubMed ID: 15040857
[TBL] [Abstract][Full Text] [Related]
20. The benefits of early androgen blockade.
Maroni PD; Crawford ED
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):317-29. PubMed ID: 18471789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
